問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Urology

Division of General Surgery

Division of Hematology & Oncology

更新時間：2023-09-19

莊正鏗cheng, Rita
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

  • qq0982700615@hotmail.com

  • qq0982700615@hotmail.com

Recruiting Trial

29Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

莊正鏗

List

70Cases

2017-02-01 - 2021-12-27

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Atezolizumab

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

2025-05-01 - 2029-03-06

Phase II

Active
A phase II, randomized, open-label, multicenter trial is being conducted to evaluate the use of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with prostate-specific cell membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

  • Condition/Disease

    PSMA-positive metastatic castration-resistant prostate cancer who had previously received at least one ARPI

  • Test Drug

    JSB462

Participate Sites
2Sites

Recruiting2Sites

2017-07-15 - 2022-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-06-15 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated4Sites

林永昌
Linkou Chang Gung Medical Foundation

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2024-06-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2013-09-01 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2021-12-30 - 2027-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2027-05-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-03-20 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB